Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionKinneret Advisory, LLC
Latest Disclosed Ownership6,397 shares
Latest Disclosed Value $ 2,856,516
Kinneret Advisory, LLC reports 4.25% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Kinneret Advisory, LLC filed a 13F-HR form disclosing ownership of 6,397 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,856,516 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 6,681 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -4.25% during the quarter. The current value of the position is $2,825,811 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,397 -284 -4.25 2,857 -5.68 0.2707
2026-02-12 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,681 -183 -2.67 3,029 12.65 0.2565
2025-11-05 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,864 -31 -0.45 2,688 -12.41 0.2288
2025-07-25 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,895 -10 -0.14 3,070 -8.31 0.2795
2025-07-21 2025-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,905 -23 -0.33 3,348 20.01 0.3374
2025-04-29 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,648 -2,280 2,253 0.3374
2025-02-03 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,928 -323 -4.45 2,790 -17.29 0.2634
2024-11-04 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,251 -95 -1.29 3,372 -2.06 0.3094
2024-07-26 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,346 -2,748 -27.22 3,443 -18.39 0.3303
2024-04-25 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,094 -31 -0.31 4,219 2.43 0.4218
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,125 -64 -0.63 4,120 16.26 0.4561
2023-10-12 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,189 -6 -0.06 3,543 -1.23 0.4377
2023-08-02 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,195 0 0.00 3,588 11.67 0.4250
2023-04-27 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,195 -548 -5.10 3,212 3.55 0.4149
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,743 -3,912 -26.69 3,102 -26.89 0.4101
2022-11-02 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,655 0 0.00 4,243 2.74 0.5886
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,655 310 2.16 4,130 10.31 0.5358
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,345 320 2.28 3,744 21.56 0.4110
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 0 0.00 3,080 21.07 0.3188
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 0 0.00 2,544 -10.04 0.2982
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 0 0.00 2,828 -6.17 0.3342
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 0 0.00 3,014 -9.08 0.3869
2021-02-11 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 0 0.00 3,315 -13.13 0.4499
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,025 -451 -3.12 3,816 -9.21 0.5784
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,476 0 0.00 4,203 22.00 0.6760
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,476 1,619 12.59 3,445 22.38 0.6710
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,857 0 0.00 2,815 29.25 0.5119
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,857 0 0.00 2,178 -7.63 0.4337
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,857 0 0.00 2,358 -0.30 0.4780
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,857 -156 -1.20 2,365 9.69 0.4977
2019-02-13 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,013 13,013 2,156 0.6384
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.